{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-021407","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.914757+00:00","generated_at":"2026-05-17T23:46:10.504663+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%","bullets":["Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.","Dr. Schalop has extensive biotech and finance background including roles at Morgan Stanley, J.P. Morgan, Credit Suisse.","Board amended By-laws to reduce stockholder quorum requirement from majority to one-third (33.33%) of shares entitled to vote.","Amendment to Section 2.07 effective immediately on July 24, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-021407","json":"https://secwatch.observer/filing/0001641172-25-021407.json","markdown":"https://secwatch.observer/filing/0001641172-25-021407.md","text":"https://secwatch.observer/filing/0001641172-25-021407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/0001641172-25-021407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:46:10.504663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a84de241aa1d3de0f55714807fc1219fe66ea241","claim":"Lantern Pharma Inc.: Reduced quorum requirement for stockholder meetings from a majority to one-third (33.33%) of shares entitled to vote (effective 2025-07-24).","evidence_excerpt":"On July 24, 2025, the Board approved an amendment to the Company’s By-laws (the “By-laws”), effective immediately. The amendment modified the provisions for determining a quorum for a meeting of stockholders of the Company and effectively reduced the quorum requirement from a majority of the shares entitled to vote at the meeting to one-third (33.33%) of the shares entitled to vote at the meeting.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/0001641172-25-021407-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-07-24"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}